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Nefopam Hydrochloride: A fatal overdose 
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 ABSTRACT 
Nefopam is a non-opiate analgesic commonly used for the treatment of moderate to severe 
pain. A case of a 37-year-old male who was found dead in the morning is presented. An 
autopsy was performed and femoral venous blood, heart blood, urine, and vitreous humour 
were submitted for toxicological analysis. A general drug screen detected the presence of 
nefopam, caffeine, nicotine, citalopram, gabapentin, amitriptyline, diazepam and 
paracetamol in cardiac blood. Nefopam was quantitated by HPLC-DAD. Nefopam was found 
at the following concentrations: 13.6 mg/L in unpreserved femoral blood; 14.7 mg/L in 
preserved (fluoride-oxalate) femoral blood; 21.2 mg/L in unpreserved cardiac blood; 4.5 
mg/L in preserved vitreous. Citalopram was present at a concentration of 0.7mg/L (femoral 
blood) and 0.9mg/L (cardiac blood). Ethanol analysed by headspace gas chromatography 
(GC-FID) was detected in preserved (fluoride-oxalate) vitreous (14 mg/ 100 mL) and 
preserved (fluoride-oxalate) urine 50 mg/ 100mL. Death was attributed to atherosclerotic 
coronary artery disease and therapeutic drug toxicity. 
 
 
 
.  
 
 
 
 
 Introduction 
To date, there have previously been 6 reports of fatal overdoses of nefopam mainly in the 
UK (1-4), but also in France (5) and New Zealand (6). This study is the first to quantify 
nefopam in vitreous humour as well as in unpreserved femoral and cardiac blood. This study 
is also only the second study to report the levels of nefopam in unpreserved femoral blood. 
Femoral blood is generally regarded as the sample in which the concentration of drugs 
changes the least between the time of death and the postmortem period. The femoral blood 
is therefore the best sample in which to accurately determine the amount of drug present at 
the time of death (7).  
This paper describes the autopsy and toxicological findings of a nefopam poisoning fatality. 
Nefopam was detected and quantitated in unpreserved and preserved femoral blood, 
unpreserved cardiac blood and we report for the first time the detection and quantitation of 
nefopam in vitreous humour. The detection and quantitation of nefopam was carried out by a 
validated method using high-performance liquid chromatography with diode-array detection 
(HPLC-DAD).    
 
Case report 
A 37 year old male was found at home lying on his stomach with no sign of life. He suffered 
from chronic pain and had a history of depression with a previous attempt at suicide via 
overdose. There was no expression by the deceased that he was intending to take his own 
life in the period before the death. Various medications were recovered from the scene and 
included naproxen, citalopram, gabapentin, omeprazole, paracetamol and diazepam. Two 
months prior to his death he was prescribed Nefopam Hydrochloride.  
Internal examination at autopsy revealed marked degenerative narrowing and hardening of 
the arteries supplying blood to the muscle of the heart (atherosclerotic coronary artery 
disease). There was no evidence of either recent or old heart attack (no acute infraction or 
myocardial fibrosis). Both lungs were heavy and congested with a large amount of fluid 
within them (pulmonary oedema). No tablets or tablet residue was discovered within the 
stomach or first part of the intestine. Histopathological examination of the retained tissues 
confirmed their macroscopic appearances at autopsy. There were small areas of scaring in 
the heart muscle in keeping with old injury due to poor flow (myocardial fibrosis) and 
evidence of narrowing of the vessels (atherosclerosis).  
 
Experimental  
Postmortem Samples 
As part of routine autopsy procedures unpreserved femoral and cardiac blood were 
collected. Preserved samples (2.5% Fluoride/Oxalate) of vitreous humour, femoral blood and 
urine were also collected to help prevent postmortem drug degradation and/or ethanol 
formation.  
Analytical materials and methods 
A stock solution of Nefopam (LGC standards, Teddington, UK) was prepared at a 
concentration of 1mg/ml in methanol (Fisher Scientific, Loughborough, U.K) and stored at 
4°C in an amber vial. This stock solution was used to prepare a seven point calibration curve 
(0.156, 0.312, 0.625, 1.25, 2.5, 5 and 10 mg/L) in blank equine plasma (TCS Biosciences, 
Buckingham, U.K). A separate stock solution of the drug was used to prepare quality control 
standards of 0.5 mg/L and 5.0 mg/L. Calibrator and control samples were prepared prior to 
each extraction.  
The extraction method for the HPLC-DAD was adapted from a previously published method 
for basic drugs (8). In brief, 500 µL of the standard/biological sample was added to a 
polypropylene test tube, and spiked with 500 µL of internal standard (5 mg/L Desipramine 
(Sigma-Aldrich-Fluka, Poole, U.K) in 0.2M Na2CO3 solution at pH 10) and followed by 
extraction with 5 ml of 1-chlorobutane (Fisher Scientific, Loughborough, U.K). After 5 
minutes of rotary mixing the sample was centrifuged at 5000 rpm for 10 minutes and the 
supernatant solvent layer was transferred to a second polypropylene test tube. A back-
extraction was carried out with 100µL of 0.05M H2SO4 (Sigma-Aldrich-Fluka, Poole, U.K). 
The extract was transferred to a vial for HPLC analysis. The injection volume was 10 µL. 
HPLC-DAD analyses were carried out using an UltiMate® 3000 UHPLC Dionex HPLC 
system (Camberley, U.K.) consisting of a DAD-3000 diode array detector, WPS-3000SL 
autosampler, LPG-3400SD low pressure quaternary pump and TCC-3000SD thermostated 
column compartment.  Data acquisition was by the Chromeleon software (version 6.8) 
package with the DAD recording spectral data between 200 and 595 nm.   
The column used for qualitative analysis was a Phenomenex Synergi Fusion column (150 X 
2.0 mm, 4 µm) protected by a 4mm x 3mm Phenomenex Synergi Fusion guard column 
(column temperature 25 oC). HPLC screening used a 4-70% acetonitrile gradient ramp in 15 
minutes with 70% acetonitrile, a hold for 3 minutes and a flow of 0.63 ml/min producing a 
total run time with equilibration of 18 minutes. The peak detected was compared with a 
toxicological library that had been updated in house from the certified reference standard. 
Quantitative HPLC-DAD analysis was performed on a Waters XSelect C18 Column, (2.1 mm 
X 150 mm, 3.5 µm) and protected by a 4mm x 3mm Phenomenex Synergi Fusion guard 
column. The mobile phase used was 25 mM triethylammonium phosphate buffer (Sigma-
Aldrich-Fluka, Poole, U.K) and far UV-grade acetonitrile (Fisher Scientific, Loughborough, 
U.K). The quantitative analysis utilised an isocratic elution with 35% acetonitrile. The total 
run time was 5 minutes and flow rate was 0.6 ml/min with a column temperature of 25°C. 
Data acquired at 230 nm wavelength was used for all quantitation 
 
Method Validation  
The Nefopam quantification method was validated to meet ISO17025 standard requirement 
and the parameters assessed were as described previously (9): linearity (r2=0.999) (Figure 
1), limit of detection (LOD = 0.01 mg/L), limit of quantification (LOQ 0.11 mg/L), precision and 
accuracy. All parameters were within acceptable limits (table 1). The intra-day precision of 
Nefopam quantitation was 10% or better, with accuracy within 95 % of low and high quality 
controls. The method showed no interfering peaks at the retention time of Nefopam when 
investigating this fatality and a calibration model using a linear fit and weighting of 1/x gave 
less than 5 % deviation from the target concentration within the linear range set between 
0.156 and 10 mg/L. None of the analytes detected in this case co-eluted with Nefopam.  
 
Results 
A general drug screen detected the presence of nefopam, caffeine, nicotine, citalopram, 
gabapentin, amitriptyline, diazepam and paracetamol in cardiac blood. Nefopam was 
quantitated by HPLC-DAD. Nefopam was found at the following concentrations: 13.6 mg/L in 
unpreserved femoral blood; 14.7 mg/L in preserved (fluoride-oxalate) femoral blood; 21.2 
mg/L in unpreserved cardiac blood; 4.5 mg/L in preserved vitreous. Citalopram was present 
at a concentration of 0.7mg/L (femoral blood) and 0.9mg/L (cardiac blood). Gabapentin 
(below 1 mg/L), amitriptyline (below 0.15 mg/L) and diazepam (below 0.15 mg/L) were all 
detected below our quantitation limit. Ethanol analysed by headspace gas chromatography 
(GC-FID) was detected in preserved (fluoride-oxalate) vitreous (14 mg/ 100 mL) and 
preserved (fluoride-oxalate) urine 50 mg/ 100mL. ).  
 Discussion 
Nefopam (Fig 1A) (Acupan, Silentan, Nefadol, Ajan, fenazoxine) is a benzoxazocine known 
as 5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine (C17H19NO) and is a cyclic 
analogue of diphenhydramine (C17H21NO) (Fig 1B). Nefopam was initially developed over 30 
years ago as a muscle relaxant (3) and antidepressant (1), but it eventually found clinical 
use as a non-opioid centrally acting analgesic drug used for relief of moderate acute and 
chronic pain (10). Unlike other analgesics, its mechanism of action is unique. Its analgesic 
activity has shown to involve inhibition of the reuptake of serotonin, noradrenaline and 
dopamine (11-14). More recent in vitro and in vivo studies in rodents have shown 
interactions with the glutamatergic system (15, 16) but the exact mechanism of action is 
currently unclear. Nefopam is sold as a racemic mixture (+/- isomers) of 30mg tablets and 
also in an injectable form (10, 17). The oral dose is initially 60 mg (elderly 30 mg) 3 times 
daily, adjusted according to response and the usual range is 30–90 mg 3 times daily. It can 
be administered by injection either intravenously or intramuscularly in 20mg doses (17). Two 
studies have been published describing the side effects of nefopam based on analysis of 
pharmacovigilance databases in France (18) and New Zealand (19) over many years. Side 
effects include nausea, vomiting, malaise, sedation, somnolence, palpitations, tachycardia 
and vertigo. More serious side effects reported are hallucinations, convulsions, confusion, 
hypotension and anaphylactic reactions (18, 19). Pharmacologically, the analgesic effect of 
nefopam has been found to be 10 times more potent than aspirin (20) and approximately 2-3 
times less potent than morphine. Nefopam does not exhibit the respiratory depressant 
effects of morphine (10). The individual isomers have differing potencies of antinociceptive 
actions with (+) nefopam > (±) nefopam > (-) nefopam.  (+) nefopam being around 7 – 30 
times more potent than (-) nefopam (13). Based on early studies it was not expected that 
nefopam would have abuse potential but in France there have been reports of intramuscular 
abuse by patients mainly for its psychostimulant effects (21-23), but to the best of the 
authors knowledge there have been no reports of oral abuse. Human pharmacokinetic 
studies have shown a peak plasma concentration of between 1 and 3 hours (90mg 
dose(20)) 1.63-1.73 h (30mg dose, (24)) and 1.83h (20mg dose (25)). Nefopam undergoes 
significant first pass metabolism as the bioavailability (F) is 0.36 ± 0.13 (25, 26). The peak 
plasma concentration (Tmax) has been reported as 0.073 – 0.155 mg/L (90mg dose, (20)) 
0.067 ± 0.002 mg/L (30mg dose, (24) and 0.012 ± 0.004 mg/L (20mg dose, (25)) When 
given intravenously (20mg) the peak plasma concentration observed was 0.046 ± 0.014 
mg/L (25) and 0.072 ± 0.014 mg/L (27). Studies have shown similar oral half-life’s (t½) in 
human studies 5.1 ± 1.3 h (25), 4.41  ±  0.16 h; 4.80 ±  0.13 h (24) and 3.8  ±  0.70 h; 4.1 ±  
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0.8 h (27), and between 3 – 8 h in both oral and intravenous studies (20). The drug 
distributes throughout the body with estimated volumes of distribution (Vd) of 410 ±  115 L; 
447 ± 98 L (27) and 535 ± 139 L (25). Nefopam is metabolised mainly to n-
desmethylnefopam, with nefopam glucuronide and nefopam-N-oxide being minor 
metabolites, all are thought to be inactive (5). Based on human trials of a dose of 20mg n-
desmethylnefopam has a t½ of 10.6 ± 3.0 h (oral) and 15.0 ± 2.4 h (i.v.), a Tmax of 2.54 h 
(oral) 5.10 h (i.v.) with peak plasma concentrations of 0.011 ± 0.004 mg/L (oral) and 0.007 ± 
0.002 mg/L (25). Nefopam is mainly eliminated by metabolism with only 5% of the dose 
being excreted unchanged in urine (20).   
There have been 6 previously reported cases of deaths involving toxicity of nefopam (1-6). 
These cases are detailed in table 2. Based on data from animal studies (28), human non-
fatal cases (2) and fatal cases it is possible to discern the clinical pattern in nefopam 
overdose. These symptoms are generalised seizures, tachycardia, generalised limb 
flaccidity, fever, acute renal failure, cerebral oedema, and finally cardiac arrest. More serious 
side effects reported are hallucinations, convulsions, confusion, hypotension and 
anaphylactic reactions. The unpreserved femoral concentration of nefopam in our case was 
13.6 mg/L is around 87 times higher the peak plasma concentration (0.155 mg/L) reported in 
human pharmacokinetic studies (20). It is also above the only other fatal concentration of 
nefopam reported in femoral blood (6.2 mg/L, (6)). The unpreserved cardiac blood 
concentration of nefopam in this case (21.2 mg/L) was also above the previously reported 
concentration of 4.38 mg/L in another fatal case  involving the injection of nefopam (5).  The 
other drug that was detected and quantitated in this case was citalopram with an 
unpreserved femoral blood concentration of 0.7mg/L and an unpreserved cardiac blood 
concentration of 0.9mg/L. This is in the range of drug concentrations of citalopram found in 
12 autopsy in deaths unrelated to citalopram usage (0.1 – 1.1 mg/L) (29).  Postmortem 
redistribution has been described as a “toxicological nightmare” where drug concentrations 
in postmortem blood may change after death (7). Drugs with a volume of distribution > 3 
L/Kg are though more likely to redistribute after death with the cardiac to femoral ratio of >1 
showing a likely distribution (7). The ratio of nefopam concentration in unpreserved cardiac 
and femoral blood was 1.6 raising the possibility that nefopam may undergo post-mortem 
redistribution. The volume of distribution in the literature has only been given in litres 
however it is possible to get an estimate using the data from the study by Aymard et al. (25) 
were the mean Vd is 535 l and the mean weight of the subjects is 74 kg. This gives a ~Vd of 
7 L/Kg. It may be that none or limited postmortem redistribution has occurred in this case as 
the citalopram cardiac:femoral ratio is 1.3  and citalopram has a Vd of 12-16 L/Kg (30) above 
the value of 3 L/Kg for drugs which are likely to undergo postmortem redistribution and has 
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been shown in 10 case to have a mean cardiac:femoral ratio of 2.5 (range 0.7-10) (30). This 
also indicates that nefopam may undergo postmortem redistribution. Unfortunately to date 
there are no publish studies with both postmortem cardiac and femoral blood concentrations 
of nefopam in which to confirm the possible postmortem redistribution of nefopam. 
The nefopam concentration in preserved femoral blood was higher than in unpreserved 
femoral blood samples by 7.4%. Although this is within the variability of analysis of analytes 
in biological matrices, it may also be the result of nefopam instability in blood as a 
consequence of the fact that benzoxazocine may be easily oxidised. Furthermore Nefopam 
is known to be unstable under acidic conditions (31). The unstable nature of nefopam 
becomes problematic post-mortem, as the pH decreases rapidly from 7.3 to 6 in the first 
hour and then further decreases to pH 5.0 by 96 hours (32). Consequently between case 
comparisons of nefopam concentrations in fatalities may prove difficult due to drug instability 
and postmortem blood concentration changes of drugs. ).  
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 Table 1: Validation data for quantitation of Nefopam in plasma, vitreous, blood and urine* 
Matrix 
 
Mean 
Concentration 
(mg/L) (± SD) 
RSD (%) Accuracy (%) 
Plasma 
Intra-day (n = 5) 
0.5 mg/L 0.49± 0.03 6.1 98.0 
5 mg/L  4.97± 0.19 3.8 99.4 
Plasma 
Inter-day (n = 15) 
0.5 mg/L 0.48± 0.02 4.2 96.0 
5 mg/L  0.52± 0.02 3.8 104 
Blood  
Intra-day (n = 5) 
0.5 mg/L 5.12± 0.13 2.5 102.4 
5 mg/L  4.99± 0.10 2.0 99.8 
Blood  
Inter-day (n = 15) 
0.5 mg/L 0.52± 0.05 9.6 104 
5 mg/L  5.02± 0.09 1.8 100.4 
Vitreous 
Intra-day (n = 5) 
0.5 mg/L 0.53± 0.02 3.8 106 
5 mg/L  4.90± 0.07 1.4 98 
Vitreous 
Inter-day (n = 15) 
0.5 mg/L 0.52± 0.02 3.8 104 
5 mg/L  4.91± 0.08 1.6 98.2 
* Equine plasma from TCS Biosciences; human SAGM blood from Blood Transfusion Service, 
Ninewells Hospital, Dundee—with ethical approval; porcine vitreous from a local butcher; human 
urine donated by laboratory staff. 
 
 
Table 2: Reported cases of fatal nefopam overdose 
Year Gender, Age Circumstances of death Other Drugs Detected 
Nefopam Concentration 
(mg/L or mg/Kg) Ref 
1981 Female (30) Suicidal Ingestion None Postmortem “serum” – 11.9 (2) 
1999 Female (38) Suicidal Ingestion Dihydrocodeine (5.9 mg/L) 
Antemortem admission 
serum – 4.3 (1) 
2001 Female (37) Suicidal injection (i.v.) None 
PM Cardiac Blood - 4.38 
Liver – 59.12 
Kidney – 14.57 
Lung – 44.07 
Myocardium – 14.87 
(5) 
2005 Male (23) Suicidal Ingestion 
Venlafaxine 
(0.7mg/L) 
Codeine 
(0.3mg/L) 
Paracetamol 
(64.0 mg/L) 
Morphine 
(0.02mg/L) 
Postmortem Blood – 35.8 (4) 
2006 Female (50) Not Given None 
PM Femoral blood – 6.2 
Liver - 57 
(6) 
2009 Male (19) Oral ingestion 60x30mg Diclofenac Postmortem “Serum”  - 7.45 (3) 
nefopam, 14x50mg diclofenac (0.069mg/L) 
 
Figure 1: The chemical structure of A) nefopam and B) diphenhydramine 
 
  
 
A) B) 
 Figure 2: Calibration curve and UV-Vis spectra for Nefopam 
 
 
